Clinical bottom line
Small fiber neuropathy (SFN) is increasingly recognized as a significant and often refractory complication in systemic autoimmune rheumatic diseases (SARDs), including systemic lupus erythematosus (SLE) and others. Novel therapeutic approaches targeting immune-mediated mechanisms show promise but remain largely investigational. Current evidence highlights the need for improved diagnostic methods and cautious interpretation of emerging therapies, which warrant further validation before routine clinical adoption.
What the evidence shows
Recent studies emphasize the high prevalence and clinical impact of SFN in patients with SARDs. McKnight et al. (2024) reported a notably high prevalence of biopsy-proven SFN in a rheumatology clinic cohort, underscoring its clinical relevance and potential underdiagnosis. Diagnostic advances such as corneal confocal microscopy (Gharib et al., 2024) and accelerometry-based methods (Veličković et al., 2023) offer promising non-invasive tools for early detection and monitoring of SFN, potentially facilitating timely intervention.
Therapeutically, evidence remains limited but evolving. Santimov et al. (2016) reviewed biological therapies in pediatric rheumatic diseases, highlighting that some biologics targeting inflammatory pathways may modulate neuropathic symptoms, though specific data on SFN are sparse. Immune modulation remains a putative mechanism for symptom improvement, but robust clinical trials specifically addressing SFN in SARDs are lacking. The complex interplay between SFN and overlapping conditions such as fibromyalgia further complicates therapeutic decisions (Wang et al., 2016).
Caveats and uncertainty
The heterogeneity of SFN manifestations and overlap with other pain syndromes in rheumatic diseases pose diagnostic and therapeutic challenges. Biopsy remains the gold standard for diagnosis but is invasive and not routinely feasible. Emerging imaging and functional assessments require validation in larger, diverse cohorts to establish sensitivity, specificity, and clinical utility (Gharib et al., 2024; Veličković et al., 2023).
Therapeutic evidence is largely extrapolated from small case series, observational studies, or biologic rationale rather than randomized controlled trials. The efficacy and safety of novel immunomodulatory agents specifically for SFN in SARDs remain unproven, and treatment responses may vary widely. Additionally, the contribution of non-inflammatory mechanisms to SFN symptoms warrants consideration, limiting the generalizability of immunotherapy approaches.
How this may change practice
Clinicians should maintain a high index of suspicion for SFN in patients with SARDs presenting with neuropathic pain or dysesthesia, especially when conventional neuropathy evaluations are inconclusive. Incorporation of emerging non-invasive diagnostic modalities such as corneal confocal microscopy may enhance early detection and monitoring, pending wider availability and validation.
While novel biologic and immunomodulatory therapies offer theoretical benefit, their use for SFN should be considered experimental and individualized, ideally within clinical trials or specialist centers. Multidisciplinary management including pain specialists and neurologists remains essential. Future integration of validated diagnostic tools and targeted therapies may improve outcomes for this challenging complication.